Our Expertise

Paul has held several senior science leadership roles in Academia and Large Pharma.  These roles focused on applying the best science in projects to ensure optimal product performance in the patient, thus bridging pharmaceutical and clinical disciplines.

Immediately prior to founding Seda Pharmaceutical Development Services Paul was Senior Clinical Pharmacology Scientist at AstraZeneca and led the clinical pharmacology program to NDA/MAA for AZD9291/osimertinib, which had been awarded ‘breakthrough therapy’ status by the FDA.  Formerly Paul was a Principal Scientist within Pharmaceutical Development (AZ) leading both the global biopharmaceutics network and the Medicines Evaluation science community (USA, SE, UK).

Paul has been at the forefront of recent advances in the understanding of in vitro performance criteria that assure product performance in the patient including clinically relevant dissolution specifications (CRDS).  Paul has co-authored papers with FDA staff focussed on efforts to combine biopharmaceutics with ICH Q8 (BioRAM) and is past Chair of the AAPS ‘QbD and product performance’ focus group.

‪Paul A Dickinson‬ – ‪Google Scholar‬

Linette is Chief Scientific Officer at Seda and leads the ADME Sciences Division, encompassing DMPK, clinical pharmacology, and modelling. She holds a BSc (Hons) and PhD in Chemistry from the Universities of Glasgow and Edinburgh, respectively.

With over 17 years at AstraZeneca, Linette held senior roles in Discovery and Early Pharmaceutical Development, where she provided expert input into compound design, selection, and progression. Her work focused on integrating physicochemical, ADME, and biopharmaceutics understanding using in vitro, in silico, and in vivo models to support candidate selection and early clinical development.

At Seda, Linette continues to provide strategic consultancy to clients while driving the scientific direction of the company. Her current focus is on translating ADME and pharmacodynamic insights into meaningful formulation and clinical study design to accelerate development and maximise product value.

‪Linette Ruston‬ – ‪Google Scholar‬

Valentina has a masters in applied mathematics and a PhD in mathematical modelling of biological systems, obtained from the University of Liverpool. In addition, she has vast experience in modelling both ordinary and partial differential equations, which helps her develop and understand pk models. At Seda Valentina is part of the modelling team, working as a senior scientist analysing preclinical and clinical data, and building models to help clients get a better understanding of the effectiveness of their compounds.

Heather has a master’s degree in mathematics from the University of Birmingham and a PhD in Mathematical Biology from the University of Nottingham. Prior to working for Seda, Heather completed a 2-year postdoc in disease modelling of metabolic dysfunction-associated steatotic liver disease with AstraZeneca in Gothenburg, Sweden. She has a broad mathematical skillset including ODE and PDE modelling as well as knowledge of machine learning classification algorithms such as random forests. Heather is working as a senior scientist in the modelling team at Seda. 

Harri is able to apply commercially available software PK-Sim, in order to form translational PB-PK modelling for different species or populations and help with dose selection in the early clinical stage settings. As a Mathematics graduate his background enables him to bring systems thinking to PK modelling to identify sources of uncertainty and risk.

‪Harri Dickinson‬ – ‪Google Scholar‬

A physics graduate, with over 3 years’ experience in the pharmaceutical industry. Jake has applied analytical, mathematical, and problem-solving skills to the assessment of the likelihood of drug candidate success and to identify the likely risks involved in the formulation of a drug. Areas of expertise include PK / PK-PD-TGI modelling in preclinical species and translation to man to aid in dose prediction. Jake has developed models and applications including Nora Max, an in silico absorption model, that aids decision making in late preclinical and early clinical drug development phases of drug development and enables the identification of the formulation technologies required for FiH.

‪Jake Dickinson‬ – ‪Google Scholar‬

First from the University of Birmingham studying Mechanical Engineering with a final year focus in biomedical engineering. Using my academic background with my interest in this area, I will be working with the modelling team within Seda.

Ashleigh has a background in both in-silico modelling and chemistry, understanding both compound analysis and the modelling approaches harnessed in drug development. During her MSc, she spent her final months developing a Mechanistic Kidney Model to predict creatinine Drug-Biomarker Interactions (DBIs) aiming to reduce false-positive predictions of Acute Kidney Injury (AKI.)

In her spare-time, she worked within community pharmacy where she gained a strong understanding of patient welfare and pharmaceutical demand.

Adam holds a first-class BSc in Mathematics and has recently completed his PhD in Mathematical Biology. Adam’s PhD work explored the influence of topography and connexin mimetic peptides (CMPs) on cutaneous wound healing using agent-based and mechanistic modelling approaches. Specifically, the work explored how tissue and substrate structure influences fibroblast cell migration behaviour, how the CMP Gap27 disrupts connexin 43 cycling dynamics and hemichannel formation and how Gap27 binding subsequently prevents within population fibroblast cell-cell interactions and cell aggregation, restoring migration into a wound region. Adam joins Seda as a Senior Modeller looking to build experience and expertise in pharmacometric modelling with a focus on developing population PK, PKPD, PBBM and PBPK models.

Alison is a Senior Principal Scientist in Clinical Pharmacology and DMPK at Seda with a PhD in Drug Metabolism from the University of Manchester and an MSc in Toxicology from the University of Birmingham. She is an experienced multidisciplinary scientist having spent over 10 years in DMPK Discovery with AstraZeneca and, for the last 10 years, specialised in PBPK modelling using GastroPlus with Quotient Sciences. At Seda she provides scientific input into Clinical Pharmacology and DMPK study design and provides interpretation and analysis of client data.

‪Alison Wilby‬ – ‪Google Scholar‬